Journal: Neurological research

Article Title: The clinical characteristics and prognostic value of IGFBP6 in glioma.

doi: 10.1080/01616412.2021.1963620

Figure Lengend Snippet: Figure 1. The expression of IGFBP6 according to WHO grades, IDH status and 1p/19q status in CGGA and TCGA datasets. (a-c) IGFBP6 was significantly increased in WHO IV, IDH wild type and 1p/19q intact glioma samples in TCGA dataset (d-f). IGFBP6 was significantly increased in WHO IV, IDH wild type and 1p/19q intact glioma samples in CGGA dataset. Photographs of immuno histochemical staining of IGFBP6 in different grades of gliomas. Positive cells are stained brown. (g) Diffuse astrocytoma (WHO grade II). (h) Anaplastic astrocytoma (WHO grade III). (i) Glioblastoma multiforme (WHO grade IV). Magnification, x200. *, **, *** and **** indicate P < 0.05, P < 0.01, P < 0.001 and P < 0.0001, respectively.

Article Snippet: IGFBP6 Monoclonal Antibody (67,567-1-Ig, dilution: 1:200, Proteintech) was used to detect IGFBP6 protein expression.

Techniques: Expressing, Staining

Journal: Neurological research

Article Title: The clinical characteristics and prognostic value of IGFBP6 in glioma.

doi: 10.1080/01616412.2021.1963620

Figure Lengend Snippet: Figure 2. The difference of IGFBP6 in four TCGA molecular markers. (a, c) The expression of IGFBP6 was significantly upregulated in mesenchymal subtype in TCGA and CGGA datasets. (b, d) The ROC curves indicated that IGFBP6 expression exhibited highly sensitivity and specificity to predict mesenchymal subtype in TCGA and CGGA datasets. Area under curve (AUC) was 0.831 and 0.858, respectively. (e) Photographs of immunohistochemical staining of IGFBP6 in gliomas with different molecular subtypes. Positive cells are stained brown. Magnification, x200.

Article Snippet: IGFBP6 Monoclonal Antibody (67,567-1-Ig, dilution: 1:200, Proteintech) was used to detect IGFBP6 protein expression.

Techniques: Expressing, Immunohistochemical staining, Staining

Journal: Neurological research

Article Title: The clinical characteristics and prognostic value of IGFBP6 in glioma.

doi: 10.1080/01616412.2021.1963620

Figure Lengend Snippet: Figure 3. The gene ontology analysis of IGFBP6. (a, b) Heatmaps show the IGFBP6-related genes in CGGA and TCGA datasets. (c) The IGFBP6 expression was positively related with immune responses, immune cell migration, regulation of JAK-STAT pathway and so on. (d) The IGFBP6 expression was negatively related with the normal physiological functions of neurons and cells.

Article Snippet: IGFBP6 Monoclonal Antibody (67,567-1-Ig, dilution: 1:200, Proteintech) was used to detect IGFBP6 protein expression.

Techniques: Expressing, Migration

Journal: Neurological research

Article Title: The clinical characteristics and prognostic value of IGFBP6 in glioma.

doi: 10.1080/01616412.2021.1963620

Figure Lengend Snippet: Figure 4. IGFBP6 related checkpoints and inflammation activities in CGGA and TCGA cohorts. (a, b) IGFBP6 expression was positively correlated with PDCD1, PDCD1L2, HAVCR2 and CD274 expression. (c, d) The relationship between IGFBP6 expression and seven inflammation activities. In pie charts, positive correlations are displayed in green and negative correlations in red. Color intensity and the size of the circle are proportional to the correlation coefficients.

Article Snippet: IGFBP6 Monoclonal Antibody (67,567-1-Ig, dilution: 1:200, Proteintech) was used to detect IGFBP6 protein expression.

Techniques: Expressing

Journal: Neurological research

Article Title: The clinical characteristics and prognostic value of IGFBP6 in glioma.

doi: 10.1080/01616412.2021.1963620

Figure Lengend Snippet: Figure 5. IGFBP6 was a prognostic factor in glioma patients. (a-f) Kaplan–Meier survival analysis showed that high expression of IGFBP6 indicated a significantly worse OS in all grade glioma patients (p < 0.0001), GBM patients (p = 0.029), IDH mutant patients (p = 0.01) and IDH wild type (p = 0.015) patients in CGGA dataset. The lower level of IGFBP6 significantly increased glioma sensitivity to radiotherapy (p = 0.002) or chemotherapy (p = 0.034) in CGGA dataset. (g-j) Kaplan–Meier survival analysis showed that high expression of IGFBP6 indicated a significantly worse OS in all grade glioma patients (p < 0.0001), GBM patients (p = 0.0061), IDH mutant patients (p = 0.0283) and IDH wild type (p = 0.0037) patients in TCGA dataset.

Article Snippet: IGFBP6 Monoclonal Antibody (67,567-1-Ig, dilution: 1:200, Proteintech) was used to detect IGFBP6 protein expression.

Techniques: Expressing, Mutagenesis

Journal: Oncotarget

Article Title: IGFBP6 is a novel nasopharyngeal carcinoma prognostic biomarker

doi: 10.18632/oncotarget.11886

Figure Lengend Snippet: IGFBP6 was detected by immunostaining in primary NPC tissues (magnification ×200). Left:, IGFBP6 positive staining; Middle: IGFBP6 negative staining; Right: isotype control staining ( A ) IGFBP6 mRNA was measured in five NPC cell lines (CNE2, CNE1, SUNE1, HK1 and HONE1) via RT-PCR, with GAPDH as an internal control ( B ) Data are representative of three separate experiments. Western blotting of whole-cell lysates to detect IGFBP6 ( C ) IGFBP6 levels in CM from NPC cells as measured by ELISA ( D ) Data are representative of two separate experiments. All data represent means ± SD from triplicates.

Article Snippet: Recombinant human IGFBP6 (rhIGFBP6) and the anti-human IGFBP6 monoclonal antibody were purchased from R&D Systems (Minneapolis, MN).

Techniques: Immunostaining, Staining, Negative Staining, Control, Reverse Transcription Polymerase Chain Reaction, Western Blot, Enzyme-linked Immunosorbent Assay

Journal: Oncotarget

Article Title: IGFBP6 is a novel nasopharyngeal carcinoma prognostic biomarker

doi: 10.18632/oncotarget.11886

Figure Lengend Snippet: Correlation of IGFBP6 expression with clinical characteristics in patients with NPC

Article Snippet: Recombinant human IGFBP6 (rhIGFBP6) and the anti-human IGFBP6 monoclonal antibody were purchased from R&D Systems (Minneapolis, MN).

Techniques: Expressing

Journal: Oncotarget

Article Title: IGFBP6 is a novel nasopharyngeal carcinoma prognostic biomarker

doi: 10.18632/oncotarget.11886

Figure Lengend Snippet: Multivariate Cox regression analysis for survival prognostic factors in advanced nasopharyngeal carcinoma

Article Snippet: Recombinant human IGFBP6 (rhIGFBP6) and the anti-human IGFBP6 monoclonal antibody were purchased from R&D Systems (Minneapolis, MN).

Techniques: Expressing

Journal: Oncotarget

Article Title: IGFBP6 is a novel nasopharyngeal carcinoma prognostic biomarker

doi: 10.18632/oncotarget.11886

Figure Lengend Snippet: CNE2 (upper panel) and HK1 (lower panel) cell proliferation as measured by MTS assay ( A ) Data represent means ± SD from six wells. * P < 0.05 compared to controls (IGFBP6 0 ng/ml). In transwell assays (upper panel), exogenous IGFBP6 inhibited CNE2 and HK1 cell invasion compared to controls ( B ) Invasive Index (%) was calculated (lower panel) according to the manufacturer's instructions. Columns, means of triplicate assays; bars, SE. ** P < 0.01 compared to controls.

Article Snippet: Recombinant human IGFBP6 (rhIGFBP6) and the anti-human IGFBP6 monoclonal antibody were purchased from R&D Systems (Minneapolis, MN).

Techniques: MTS Assay

Journal: Oncotarget

Article Title: IGFBP6 is a novel nasopharyngeal carcinoma prognostic biomarker

doi: 10.18632/oncotarget.11886

Figure Lengend Snippet: CNE2 cells were stably transfected with IGFBP6-shRNA. Real-time RT-PCR confirmed knockdown efficiency ( A ) Bars, ± SE. Data are representative of three separate experiments. Western blotting confirmed IGFBP6 knockdown ( B ) IGFBP6 knockdown induced tumor cell proliferation compared to controls ( C ) Representative wound-healing assay images ( D ) IGFBP6 knockdown increased tumor cell migration ( E ) Data represent means ± SD. * P < 0.05 compared to controls. Western blotting revealed GSK3β/β-catenin/cylin D1 pathway activation as a result of IGFBP6 knockdown ( F ).

Article Snippet: Recombinant human IGFBP6 (rhIGFBP6) and the anti-human IGFBP6 monoclonal antibody were purchased from R&D Systems (Minneapolis, MN).

Techniques: Stable Transfection, Transfection, shRNA, Quantitative RT-PCR, Knockdown, Western Blot, Wound Healing Assay, Migration, Activation Assay

Journal: Oncotarget

Article Title: IGFBP6 is a novel nasopharyngeal carcinoma prognostic biomarker

doi: 10.18632/oncotarget.11886

Figure Lengend Snippet: Silencing IGFBP6 expression in CNE2 cells promotes tumor metastasis in a mouse model

Article Snippet: Recombinant human IGFBP6 (rhIGFBP6) and the anti-human IGFBP6 monoclonal antibody were purchased from R&D Systems (Minneapolis, MN).

Techniques: Expressing